Please assess the completion status of the following clinical trial:

Trial Title: 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes~* Have inadequate overall glycemic control (hemoglobin A1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to Visit 1~* Have used:~  * single or multiple OAMs for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or~ * insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or~ * a combination of the above.~* Are greater than or equal to 21 and less than 80 years of age~* As determined by the investigator, are capable and willing to:~  * comply with their prescribed diet and medication regimen,~ * perform self blood glucose monitoring,~ * use the patient diary as required for this protocol,~ * participate in two 24 hour inpatient assessments~Exclusion Criteria:~* Have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study~* Are currently treated with a meglitinide without sulfonylurea~* Have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin~* Have plasma creatinine greater than or equal to 1.5 mg/dL (for males) or greater than or equal to 1.4 mg/dL (for females) for patients who will be treated with metformin or; greater than 2 mg/dL for patients treated with other OAMs, as determined by a local laboratory~* Have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to Visit 1

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
- 2 (Type: ACTIVE_COMPARATOR): Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).